Amphastar Pharmaceuticals Files 10-Q for Q1 2025
Ticker: AMPH · Form: 10-Q · Filed: May 8, 2025 · CIK: 1297184
| Field | Detail |
|---|---|
| Company | Amphastar Pharmaceuticals, Inc. (AMPH) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, equity, share-repurchase
Related Tickers: AMPH
TL;DR
AMPH Q1 2025 10-Q filed. Equity details and buyback info updated.
AI Summary
Amphastar Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information including common stock, retained earnings, and additional paid-in capital as of March 31, 2025. It also references share repurchase plans initiated in November 2014.
Why It Matters
This filing provides investors with an update on Amphastar's financial health and equity structure for the first quarter of 2025, including details on share repurchases.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial data)
Key Players & Entities
- Amphastar Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- 2025-03-31 (date) — End of the reporting period
- November 2014 (date) — Date of share repurchase plan initiation
FAQ
What were the total assets and liabilities as of March 31, 2025?
The provided excerpt does not contain specific figures for total assets and liabilities.
What was Amphastar's net income for the first quarter of 2025?
The excerpt does not specify the net income for the first quarter of 2025.
How much was repurchased under the November 2014 plan during Q1 2025?
The excerpt indicates activity related to the November 2014 share repurchase plan for the period of January 1, 2025, to March 31, 2025, but does not provide a specific dollar amount for repurchases during this period.
What is the current status of Amphastar's common stock as of March 31, 2025?
As of March 31, 2025, Amphastar Pharmaceuticals, Inc. had common stock, retained earnings, additional paid-in capital, and accumulated other comprehensive income, with treasury stock also noted.
Does the filing mention any new debt or significant capital expenditures?
The filing references 'LongTermDebtAndCapitalLeaseObligations' but does not provide specific details or amounts within this excerpt.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Amphastar Pharmaceuticals, Inc. (AMPH).